Payers are not overly worried about the cost of bladder cancer, due to the relatively small patient population in comparison to other solid tumors. However, with immunotherapies gaining approvals across multiple indications, payers are concerned about the rising spend on these high-cost treatments across the broader oncology market, and suggest that further access controls may need to be implemented in future.

This Datamonitor Healthcare report contains a Pricing & Reimbursement module.